Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Pancreatic Neoplasms 1Melanoma 1Lung Neoplasms 1Head and Neck Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Breast Neoplasms 1

Interventions

pembrolizumab 29Carboplatin 10Surveys and Questionnaires 9Paclitaxel 9Trastuzumab 8Nivolumab 8Cisplatin 8Taxes 7Gemcitabine 7Bevacizumab 6Specimen Handling 5Oxaliplatin 5Irinotecan 5Fluorouracil 5Cetuximab 5Biopsy 5spartalizumab 4Leucovorin 4Ipilimumab 4Docetaxel 4Cyclophosphamide 4tisotumab vedotin 3fludarabine 3durvalumab 3atezolizumab 3aldesleukin 3X-Rays 3Psychiatric Rehabilitation 3Magnetic Resonance Spectroscopy 3Interviews as Topic 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Endometrial Neoplasms × parsaclisib × Gastrointestinal × Clear all
NCT02646748 2022-03-31

Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors

Incyte Corporation

Phase 1 Completed
159 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Breast Neoplasms, Carcinoma, Renal Cell, Head and Neck Neoplasms, Lung Neoplasms, Melanoma, Pancreatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡